Journal of Infectious Diseases Advance Access published August 28, 2014
1 Antibody-dependent effector functions against HIV decline in subjects on
cr ipt
antiretroviral therapy
Vijaya Madhavi1, Fernanda E. Ana-Sosa-Batiz1, Sinthujan Jegaskanda1, Rob J.
David A. Cooper2, Anthony D. Kelleher2, Denise Hsu2, Sarah Pett2,4, Ivan
1
us
Stratov1, Marit Kramski1,# and Stephen J. Kent1,*,#
Department of Microbiology and Immunology, The University of Melbourne at the
Peter Doherty Institute for Infection and Immunity, Parkville, Victoria 3010, Australia Kirby Institute, University of NSW, 2145 Australia
3
Thai Red Cross AIDS Research Centre, HIV Netherlands Australia Thailand
an
2
4
MRC Clinical Trials Unit at UCL Research Department of Infection and Population
Health, UCL, UK
Correspondence: Stephen Kent, MD, Department of Microbiology and Immunology,
pt ed
*
M
Research Collaboration, Bangkok, Thailand
The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria 3010, Australia ([email protected]) ^
Author current affiliation at the Burnet Institute, Melbourne, Victoria 3004, Australia Contributed equally
Ac
ce
#
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e‐mail: [email protected].
Downloaded from http://jid.oxfordjournals.org/ at Periodicals Dept University Libraries Northern Illinois University on August 31, 2014
Center1,^, Wendy R. Winnall1, Matthew S. Parsons1, Jintanat Ananworanich3,
2 Abstract Background
cr ipt
Combination anti-retroviral therapy (cART) effectively controls HIV infection but does not eliminate HIV and life-long treatment is therefore required. HIV-specific
other HIV-specific immune responses that may assist in eliminating latent HIV
us
infection, specifically antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP), are unclear. Methods
an
A cohort of 49 cART-naive HIV-infected subjects from Thailand (mean baseline CD4 count 188 cells/µl and mean viral load 5.4 log10 copies/ml) was followed for 96 weeks
M
after initiating cART. ADCC and ADP assays were performed using serum samples from baseline and after 96 weeks of cART. Results
pt ed
A 35% reduction in HIV-1 Envelope (Env)-specific ADCC-mediated killing of target cells (p
1 Antibody-dependent effector functions against HIV decline in subjects on
cr ipt
antiretroviral therapy
Vijaya Madhavi1, Fernanda E. Ana-Sosa-Batiz1, Sinthujan Jegaskanda1, Rob J.
David A. Cooper2, Anthony D. Kelleher2, Denise Hsu2, Sarah Pett2,4, Ivan
1
us
Stratov1, Marit Kramski1,# and Stephen J. Kent1,*,#
Department of Microbiology and Immunology, The University of Melbourne at the
Peter Doherty Institute for Infection and Immunity, Parkville, Victoria 3010, Australia Kirby Institute, University of NSW, 2145 Australia
3
Thai Red Cross AIDS Research Centre, HIV Netherlands Australia Thailand
an
2
4
MRC Clinical Trials Unit at UCL Research Department of Infection and Population
Health, UCL, UK
Correspondence: Stephen Kent, MD, Department of Microbiology and Immunology,
pt ed
*
M
Research Collaboration, Bangkok, Thailand
The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria 3010, Australia ([email protected]) ^
Author current affiliation at the Burnet Institute, Melbourne, Victoria 3004, Australia Contributed equally
Ac
ce
#
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e‐mail: [email protected].
Downloaded from http://jid.oxfordjournals.org/ at Periodicals Dept University Libraries Northern Illinois University on August 31, 2014
Center1,^, Wendy R. Winnall1, Matthew S. Parsons1, Jintanat Ananworanich3,
2 Abstract Background
cr ipt
Combination anti-retroviral therapy (cART) effectively controls HIV infection but does not eliminate HIV and life-long treatment is therefore required. HIV-specific
other HIV-specific immune responses that may assist in eliminating latent HIV
us
infection, specifically antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP), are unclear. Methods
an
A cohort of 49 cART-naive HIV-infected subjects from Thailand (mean baseline CD4 count 188 cells/µl and mean viral load 5.4 log10 copies/ml) was followed for 96 weeks
M
after initiating cART. ADCC and ADP assays were performed using serum samples from baseline and after 96 weeks of cART. Results
pt ed
A 35% reduction in HIV-1 Envelope (Env)-specific ADCC-mediated killing of target cells (p
